anti-CD33 immunotoxin M195 (IgG)-PE (CAT#: AGTO-L050E)

• Optimistic results
  The results from anti-CD33 immunotoxin M195 (IgG)-PE have been very optimistic.
• Less invasive
  Anti-CD33 immunotoxin M195 (IgG)-PE is less invasive than traditional chemotherapy.
• Highly recommended
  I highly recommend anti-CD33 immunotoxin M195 (IgG)-PE for anyone studying AML.

1. Q 1: What is the main purpose of M195 (IgG)-PE, the anti-CD33 immunotoxin?

   A: The anti-CD33 immunotoxin M195 (IgG)-PE targets CD33 markers on leukemic cells. By binding to these markers, the immunotoxin facilitates the destruction of leukemic cells through a cytotoxic payload. Specifically, the Pseudomonas exotoxin portion of the immunotoxin interferes with the protein synthesis of the targeted cells, leading to their apoptosis.

2. Q 2: In comparison to other immunotoxins, how is anti-CD33 immunotoxin M195 (IgG)-PE different?

   A: Anti-CD33 immunotoxin M195 (IgG)-PE is distinct in its specific targeting of the CD33 antigen on leukemic cells. It combines the targeting ability of an anti-CD33 antibody with the cytotoxic action of Pseudomonas exotoxin. Its unique mechanism reduces off-target effects and enhances specificity compared to other broader immunotoxins.

3. Q 3: What role does anti-CD33 immunotoxin M195 (IgG)-PE play in the larger immunotherapy context?

   A: Anti-CD33 immunotoxin M195 (IgG)-PE is part of the growing field of immunotherapy, which leverages the body's immune system to fight cancer. Unlike traditional immunotherapies that broadly modulate immune responses, this treatment combines a targeted antibody with a cytotoxic agent, offering a precise and potent approach to eradicate cancer cells.

View the frequently asked questions answered by Creative Biolabs Support.